Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 12, 2023
Share
Sunmax Biotechnology Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 475.52 million compared to TWD 364.76 million a year ago. Revenue was TWD 473.94 million compared to TWD 363.59 million a year ago. Net income was TWD 184.43 million compared to TWD 137.32 million a year ago. Basic earnings per share from continuing operations was TWD 3.39 compared to TWD 2.52 a year ago. Diluted earnings per share from continuing operations was TWD 3.38 compared to TWD 2.52 a year ago.
For the nine months, sales was TWD 1,292.15 million compared to TWD 1,012.26 million a year ago. Revenue was TWD 1,284.47 million compared to TWD 1,010.31 million a year ago. Net income was TWD 457.12 million compared to TWD 409.28 million a year ago. Basic earnings per share from continuing operations was TWD 8.39 compared to TWD 7.51 a year ago. Diluted earnings per share from continuing operations was TWD 8.38 compared to TWD 7.51 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.